Skip to content

EBITDA margin at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-32%-10.7pp
ALN
Alnylam PharmaceuticalsALNY
18.8%+16.9pp
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-15,289.6%-16,725pp
Beam Therapeutics logo
Beam TherapeuticsBEAM
-212.9%-85.3pp
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-122.6%-30.1pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-543.2%-271pp

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.17B+106%

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Calculated from Intellia Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's EBITDA margin?
Intellia Therapeutics (NTLA) reported EBITDA margin of -622.2% in Q1 2026.
How has Intellia Therapeutics's EBITDA margin changed year-over-year?
Intellia Therapeutics's EBITDA margin increased by 46.6% year-over-year, from -1,164.8% to -622.2%.
What is the long-term trend for Intellia Therapeutics's EBITDA margin?
Over 5 years (2020 to 2025), Intellia Therapeutics's EBITDA margin has grown at a 23.2% compound annual growth rate (CAGR), from -224.6% to -637.2%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.